ATE249046T1 - Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können - Google Patents

Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können

Info

Publication number
ATE249046T1
ATE249046T1 AT97923067T AT97923067T ATE249046T1 AT E249046 T1 ATE249046 T1 AT E249046T1 AT 97923067 T AT97923067 T AT 97923067T AT 97923067 T AT97923067 T AT 97923067T AT E249046 T1 ATE249046 T1 AT E249046T1
Authority
AT
Austria
Prior art keywords
chaperones
prpsc
prpc
isoforms
differentiate
Prior art date
Application number
AT97923067T
Other languages
English (en)
Inventor
Ernst-Ludwig Winnacker
Stefan Weiss
Frank Edenhofer
Roman Rieger
Original Assignee
Winnacker Ernst Ludwig Prof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winnacker Ernst Ludwig Prof filed Critical Winnacker Ernst Ludwig Prof
Application granted granted Critical
Publication of ATE249046T1 publication Critical patent/ATE249046T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
AT97923067T 1996-05-14 1997-05-13 Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können ATE249046T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96107677 1996-05-14
PCT/EP1997/002444 WO1997043649A1 (en) 1996-05-14 1997-05-13 CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿

Publications (1)

Publication Number Publication Date
ATE249046T1 true ATE249046T1 (de) 2003-09-15

Family

ID=8222782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923067T ATE249046T1 (de) 1996-05-14 1997-05-13 Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können

Country Status (6)

Country Link
US (2) US6451541B1 (de)
EP (1) EP0914614B1 (de)
JP (1) JP3745380B2 (de)
AT (1) ATE249046T1 (de)
DE (1) DE69724619T2 (de)
WO (1) WO1997043649A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186662A3 (de) * 1996-05-29 2003-01-15 McGILL UNIVERSITY Prionbindendes Proteine und deren Verwendungen
US6720355B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Sodium dodecyl sulfate compositions for inactivating prions
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US6620629B1 (en) 1997-02-21 2003-09-16 The Regents Of The University Of California Method for detecting prions
US6719988B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Antiseptic compositions for inactivating prions
US6617119B2 (en) 1997-02-21 2003-09-09 The Regents Of The University Of California Assay for specific strains of multiple disease related conformations of a protein
AU764888B2 (en) * 1997-02-21 2003-09-04 Regents Of The University Of California, The Assay for disease related conformation of a protein
US6221614B1 (en) 1997-02-21 2001-04-24 The Regents Of The University Of California Removal of prions from blood, plasma and other liquids
US5977324A (en) * 1998-02-20 1999-11-02 The Regents Of The University Of California Process for concentrating protein with disease-related conformation
US6214565B1 (en) 1998-10-09 2001-04-10 The Regents Of The University Of California Assay for disease related conformation of a protein and isolating same
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
WO2001023894A1 (de) * 1999-09-28 2001-04-05 Evotec Oai Ag Quantitative analyse und typisierung subzellulärer partikel
EP1216258A1 (de) * 1999-09-28 2002-06-26 Universität Zürich Faktoren mit prionen bindender aktivität im serum und plasma sowie mittel zur bestimmung von übertragbaren spongiformen encephalopathien
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
JP4235544B2 (ja) 2001-05-31 2009-03-11 アドライフ インコーポレーティッド 欠陥折畳み蛋白質センサー方法
EP1414846A2 (de) * 2001-08-10 2004-05-06 Medical Research Council P53-stabilisierendes peptid
EP1572937B1 (de) * 2002-04-09 2012-02-08 The Scripps Research Institute Hybrid-polypeptide mit eingefügten sequenzmotiven und ihre verwendungen
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
JP4485367B2 (ja) 2002-12-03 2010-06-23 パソゲン リムーバル アンド ダイアグノスティック テクノロジーズ インコーポレイテッド プリオンタンパク質リガンドおよび使用方法
CN1842707B (zh) 2003-04-04 2012-06-27 病毒去除和诊断科技公司 朊病毒蛋白结合材料及其使用方法
CN101166976B (zh) * 2005-01-13 2013-06-12 诺华疫苗和诊断公司 利用朊病毒特异性肽试剂的elisa试验
JP5048522B2 (ja) * 2005-02-15 2012-10-17 エイディーライフ インコーポレイティッド 誤って折り畳まれたタンパク質およびプリオンを検出する方法
EP1982189A4 (de) * 2006-01-27 2010-09-08 Univ Leland Stanford Junior Zusammensetzungen und verfahren für screening mit hohem durchsatz von pharmakologischen chaperonen
MX2009001079A (es) * 2006-07-28 2009-02-10 Adlyfe Inc Sondas de peptido para diagnosis y terapeutica.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
AU4376093A (en) * 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
HU224160B1 (hu) * 1994-12-21 2005-06-28 Yeda Research And Development Co. Ltd. P277 Peptidanalógok, ezek alkalmazása a diabétesz in vitro diagnosztizálására szolgáló gyógyszerkészítmények előállítására, gyógyszerkészítmények és diagnosztikus kit
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
EP0914614B1 (de) 2003-09-03
JP3745380B2 (ja) 2006-02-15
US20050227287A1 (en) 2005-10-13
JP2000516572A (ja) 2000-12-12
DE69724619T2 (de) 2004-07-01
US6451541B1 (en) 2002-09-17
WO1997043649A1 (en) 1997-11-20
DE69724619D1 (de) 2003-10-09
EP0914614A1 (de) 1999-05-12

Similar Documents

Publication Publication Date Title
ATE249046T1 (de) Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
NO20100264L (no) Forhindring og behandling av amyloidogen sykdom
CY1117925T1 (el) Μεθοδος αγωγης και βιοπροσδιορισμος που σχετιζεται με παραγοντα αναστολης της μεταναστευσης των μακροφαγων (mif) ως προερχομενο απο την καρδια μυοκαρδιακο κατασταλτικο παραγοντα
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
PT938326E (pt) Fosfopeptidos de sintese para o tratamento de doencas dos ossos
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE59608213D1 (de) Arzneimittel zur immuntherapie, enthaltend antikörper, die spezifisch das mhcii-antigen eines zu behandelnden patienten erkennen
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
ATE198278T1 (de) Verwendung von sulodexid und von arzneimitteln, die dieses enthalten, zur behandlung der diabetischen nephropathie
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
Rich et al. Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
ATE198990T1 (de) Konjugat zur behandlung von entzündlichen erkrankungen
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties